Covid 19 Vaccine News

Bharat Biotech defends higher Covaxin price says ‘₹150 not sustainable’

Bharat Biotech defends higher Covaxin price says ‘₹150 not sustainable’

New Delhi: Indian vaccine manufacturer, Bharat Biotech, defended a higher price for its Covid vaccine ‘Covaxin’, saying the current rate at which the vaccine is being supplied to the central government is not sustainable, hence, a higher price in private markets is required to offset part of the costs. “The supply

Covishield produced more antibodies against Covid-19 than Covaxin: Study

Covishield produced more antibodies against Covid-19 than Covaxin: Study

New Delhi: Serum Institute of India’s Covishield vaccine produced more antibodies than indigenously manufactured Covaxin by Bharat Biotech, according to a preliminary study by Coronavirus Vaccine-induced Antibody Titre (COVAT) involving healthcare workers (HCW) who have received both doses of either of the two vaccines. As per the study, seropositivity rates to

China authorises Covid-19 vaccine ‘CoronaVac’ for children above 3 yrs

China authorises Covid-19 vaccine ‘CoronaVac’ for children above 3 yrs

Beijing : China has reportedly authorised the emergency use of its indigenously manufactured Covid-19 vaccine, CoronaVac, for children aged between 3 and 17 years. The vaccine is manufactured by Chinese firm Sinovac. “But when the vaccine will be put into (emergency) use, and starting from what age in the group has

Kamala Harris dials PM Modi as US sets to supply 25 mn vaccines to India

Kamala Harris dials PM Modi as US sets to supply 25 mn vaccines to India

New Delhi: The United States Vice President Kamala D Harris on Thursday dialed Prime Minister Narendra Modi to discuss US’s “Strategy for Global Vaccine Sharing” as the country prepares to supply 25 million Covid-19 doses to India that US plans to supply under a larger framework. She also called President Andres

India likely to get Pfizer’s vaccine against Covid-19 in July

India likely to get Pfizer’s vaccine against Covid-19 in July

New Delhi: As the government India is relaxing regulatory norms for clearing foreign-made vaccines for use and giving indemnity waiver to facilitate supply of Pfizer’s vaccine against Covid-19 in the country, officials hope to get it by July. The final agreement between the government and the American drug-maker on indemnity